912
Participants
Start Date
September 14, 2022
Primary Completion Date
June 2, 2024
Study Completion Date
June 2, 2024
L9LS
Administered subcutaneously.
Placebo
Normal saline administered subcutaneously.
Kenya Medical Research Institute (KEMRI) Center for Global Health Research (CGHR), Kisumu
Collaborators (1)
Centers for Disease Control and Prevention
FED
National Institutes of Health (NIH)
NIH
Kenya Medical Research Institute
OTHER
Liverpool School of Tropical Medicine
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH